Subscribe To
LLY / Eli Lilly Stock Cools Despite Big Cancer Investment
LLY News
By The Motley Fool
November 3, 2023
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo No more_horizontal
By CNBC Television
November 2, 2023
Expect Eli Lilly's momentum to continue, says Bank of America's Geoff Meacham
Geoff Meacham, Bank of America senior pharmaceutical analyst, joins 'The Exchange' to discuss Eli Lilly's performance, the demand outlook for weight l more_horizontal
By Zacks Investment Research
November 2, 2023
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be wor more_horizontal
By Yahoo Finance
November 2, 2023
Novo Nordisk, Eli Lilly stocks see boost on obesity drugs
Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozem more_horizontal
By The Motley Fool
November 2, 2023
Why Eli Lilly Stock Is Jumping Today
Lilly's Q3 revenue soared, but its earnings sank. However, the company's top- and bottom-line results handily beat Wall Street estimates. more_horizontal
By CNBC Television
November 2, 2023
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
CNBC's Joe Kernen reports on the company's quarterly earnings results. more_horizontal
By Barrons
November 2, 2023
Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically
Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9. more_horizontal
By Market Watch
November 2, 2023
Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed
Shares of Eli Lilly & Co. LLY, +0.10% dropped 1.8% in premarket trading Thursday, after the drug giant reported a surprise third-quarter profit but sl more_horizontal